Before Coming to the Conclusion That Inclusion Body Myositis Is a Risk Factor for a Heart Attack, All Influencing Factors Must Be Taken Into Account.
作者信息
Finsterer Josef, Zarrouk Sinda
机构信息
Department of Neurology, Neurology and Neurophysiology Center, Vienna, Austria.
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
出版信息
Eur J Neurol. 2025 Jul;32(7):e70297. doi: 10.1111/ene.70297.
Abstract
摘要
相似文献
1
Before Coming to the Conclusion That Inclusion Body Myositis Is a Risk Factor for a Heart Attack, All Influencing Factors Must Be Taken Into Account.
Eur J Neurol. 2025 Jul;32(7):e70297. doi: 10.1111/ene.70297.
2
Reply to: "Before Coming to the Conclusion That Inclusion Body Myositis Is a Risk Factor for a Heart Attack, All Influencing Factors Must Be Taken Into Account".
Eur J Neurol. 2025 Jul;32(7):e70295. doi: 10.1111/ene.70295.
3
Beta-blockers in patients without heart failure after myocardial infarction.
Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD012565. doi: 10.1002/14651858.CD012565.pub2.
4
Remote ischaemic preconditioning for coronary artery bypass grafting (with or without valve surgery).
Cochrane Database Syst Rev. 2017 May 5;5(5):CD011719. doi: 10.1002/14651858.CD011719.pub3.
5
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.
Cochrane Database Syst Rev. 2022 Feb 24;2(2):CD013556. doi: 10.1002/14651858.CD013556.pub2.
6
Education support services for improving school engagement and academic performance of children and adolescents with a chronic health condition.
Cochrane Database Syst Rev. 2023 Feb 8;2(2):CD011538. doi: 10.1002/14651858.CD011538.pub2.
7
Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of cardiovascular diseases.
Cochrane Database Syst Rev. 2025 May 6;5(5):CD013729. doi: 10.1002/14651858.CD013729.pub2.
8
A systematic review and economic evaluation of statins for the prevention of coronary events.
Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. doi: 10.3310/hta11140.
9
Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.
Cochrane Database Syst Rev. 2024 Sep 19;9(9):CD014741. doi: 10.1002/14651858.CD014741.pub2.
10
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
本文引用的文献
1
Increased Risk of Myocardial Infarction in Inclusion Body Myositis: A Non-Concurrent Cohort Study.
Eur J Neurol. 2025 May;32(5):e70177. doi: 10.1111/ene.70177.
2
Inclusion Body Myositis and Neoplasia: A Narrative Review.
Int J Mol Sci. 2022 Jul 1;23(13):7358. doi: 10.3390/ijms23137358.
3
Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study.
Br J Haematol. 2021 Jun;193(6):1194-1202. doi: 10.1111/bjh.17388. Epub 2021 Mar 21.
4
Use of oral corticosteroids and the risk of acute myocardial infarction.
Atherosclerosis. 2007 Jun;192(2):376-83. doi: 10.1016/j.atherosclerosis.2006.05.019. Epub 2006 Jun 19.
5
Physical exercise and reduced risk of nonfatal myocardial infarction.
Am J Epidemiol. 1995 Dec 1;142(11):1147-56. doi: 10.1093/oxfordjournals.aje.a117573.
Zotero 插件